A detailed history of Rhumbline Advisers transactions in Chimerix Inc stock. As of the latest transaction made, Rhumbline Advisers holds 3,730 shares of CMRX stock, worth $3,319. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,730
Previous 5,391 30.81%
Holding current value
$3,319
Previous $5,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$0.87 - $1.05 $1,445 - $1,744
-1,661 Reduced 30.81%
3,730 $3,000
Q3 2023

Nov 09, 2023

SELL
$0.94 - $1.23 $5,399 - $7,065
-5,744 Reduced 51.59%
5,391 $5,000
Q2 2023

Aug 08, 2023

SELL
$1.1 - $1.54 $115,533 - $161,746
-105,030 Reduced 90.41%
11,135 $13,000
Q1 2023

May 11, 2023

SELL
$1.19 - $2.09 $10,720 - $18,828
-9,009 Reduced 7.2%
116,165 $146,000
Q4 2022

Feb 14, 2023

BUY
$1.67 - $2.35 $4,238 - $5,964
2,538 Added 2.07%
125,174 $233,000
Q3 2022

Nov 10, 2022

BUY
$1.81 - $2.76 $25,159 - $38,364
13,900 Added 12.78%
122,636 $237,000
Q2 2022

Aug 11, 2022

BUY
$1.34 - $5.34 $12,361 - $49,261
9,225 Added 9.27%
108,736 $226,000
Q1 2022

May 12, 2022

BUY
$4.58 - $6.8 $261 - $387
57 Added 0.06%
99,511 $456,000
Q4 2021

Feb 10, 2022

BUY
$5.23 - $7.18 $4,837 - $6,641
925 Added 0.94%
99,454 $639,000
Q3 2021

Nov 12, 2021

BUY
$5.94 - $8.75 $34,410 - $50,688
5,793 Added 6.25%
98,529 $610,000
Q2 2021

Aug 05, 2021

SELL
$7.54 - $9.79 $54,665 - $70,977
-7,250 Reduced 7.25%
92,736 $742,000
Q1 2021

May 06, 2021

BUY
$4.76 - $11.25 $12,495 - $29,531
2,625 Added 2.7%
99,986 $964,000
Q4 2020

Feb 10, 2021

BUY
$2.43 - $5.42 $25,237 - $56,292
10,386 Added 11.94%
97,361 $470,000
Q3 2020

Nov 12, 2020

SELL
$2.3 - $3.72 $23,646 - $38,245
-10,281 Reduced 10.57%
86,975 $217,000
Q2 2020

Aug 13, 2020

BUY
$1.33 - $3.63 $26,361 - $71,950
19,821 Added 25.6%
97,256 $301,000
Q4 2019

Feb 05, 2020

SELL
$1.3 - $2.72 $12,912 - $27,017
-9,933 Reduced 11.37%
77,435 $157,000
Q3 2019

Oct 23, 2019

BUY
$1.93 - $4.21 $12,313 - $26,859
6,380 Added 7.88%
87,368 $205,000
Q2 2019

Aug 14, 2019

BUY
$2.05 - $4.32 $33,943 - $71,530
16,558 Added 25.7%
80,988 $350,000
Q1 2019

May 01, 2019

SELL
$1.79 - $3.12 $2,532 - $4,414
-1,415 Reduced 2.15%
64,430 $135,000
Q4 2018

Jan 31, 2019

BUY
$2.24 - $3.9 $46,264 - $80,550
20,654 Added 45.7%
65,845 $169,000
Q3 2018

Nov 07, 2018

BUY
$3.58 - $4.9 $358 - $490
100 Added 0.22%
45,191 $176,000
Q2 2018

Aug 06, 2018

SELL
$4.43 - $5.14 $8,638 - $10,023
-1,950 Reduced 4.15%
45,091 $215,000
Q1 2018

May 02, 2018

SELL
$4.65 - $5.9 $9,207 - $11,682
-1,980 Reduced 4.04%
47,041 $245,000
Q3 2017

Nov 06, 2017

BUY
$4.35 - $5.25 $213,241 - $257,360
49,021
49,021 $257,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $78M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.